Data Science and Artificial Intelligence - Turning Data into Knowledge
Our collaboration with BenevolentAI uses machine learning and AI to discover potential new drugs targets for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF). By combining our disease area expertise and large, diverse data sets with BenevolentAI’s leading AI and machine learning capabilities we hope to improve our understanding of complex disease biology and more quickly identify new drug targets.
To find out more about how data science and AI have the potential to transform drug discovery and development visit: https://www.astrazeneca.com/what-scie....
----------------------------------------
Global site: https://www.astrazeneca.com/
Careers site: https://careers.astrazeneca.com/
Follow us:
Twitter: / astrazeneca
LinkedIn: / astrazeneca
Instagram: / astrazeneca
Facebook: / astrazeneca